http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200425914-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0feed70184dfe1ee6443d2d45ad817e2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 |
| filingDate | 2001-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_451af8628f6dd07add8b88e09fa7c945 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20938f9638915bab612f5b39a57be49c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_150d87d5ea3dd97f97d7f15f03ea99ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75436ff4e5c457ec71ff61405b3682c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_412071e62f8841e653ec4363694a5725 |
| publicationDate | 2004-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-200425914-A |
| titleOfInvention | Pharmaceutical tablet composition comprising n-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide (sb 207266) or a salt thereof |
| abstract | The present invention relates to a pharmaceutical composition being a tablet for human oral administration, comprising N-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxa mide (SB 207266) or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable solid carrier, wherein the SB 207266 or the salt thereof is present in the tablet in at least 5.0 mg per 250 mg of tablet weight (measured as the free base), wherein the tablet is the result of a granulation process, and wherein the composition includes dicalcium phosphate. Preferably, the composition is substantially as follows, provided that the dose of the SB-207266 in the composition can be increased: SB-207266 5.0 mg Microcrystalline cellulose 50.0 mg Hydroxypropylmethylcellulose (HPMC) 12.5 mg Sodium starch glycollate 12.5 mg Dicalcium phosphate 167.5 mg Magnesium stearate 2.5 mg Tablet weight 250 mg. |
| priorityDate | 2000-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.